Login to Your Account

Financings Roundup

Anergis Picks up $19.6M in First VC Round Since Founding

By Nuala Moran

Tuesday, March 29, 2011
LONDON – Anergis SA raised CHF18 million (US$19.6 million) in a Series A round to fund the development of allergy vaccines based on synthetic versions of natural allergens, which it said will be able to induce tolerance more quickly than is the case with de-sensitizing through the long-term administration of natural allergens.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription